Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage.
暂无分享,去创建一个
J. Kramer | F. Elahi | A. Boxer | A. Karydas | G. Rabinovici | R. La Joie | C. Lindbergh | A. Staffaroni | Breton M. Asken | A. Strom | K. Casaletto | J. Rojas | M. You | S. Weiner-Light | Paul Wang | B. Miller | Alexandra C Apple | Nivetha Brathaban | N. Fernandes | B. Miller | Michelle You | Sophia Weiner-Light
[1] G. Kovacs. Astroglia and Tau: New Perspectives , 2020, Frontiers in Aging Neuroscience.
[2] Albert Hofman,et al. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study , 2020, Brain : a journal of neurology.
[3] G. Frisoni,et al. Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.
[4] D. Harvey,et al. Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer's disease , 2019, Alzheimer's & Dementia.
[5] Nazanin Mirzaei,et al. Ablation of reactive astrocytes exacerbates disease pathology in a model of Alzheimer's disease , 2019, Glia.
[6] L. Tan,et al. Neurofilament Light Chain in Cerebrospinal Fluid and Blood as a Biomarker for Neurodegenerative Diseases: A Systematic Review and Meta-Analysis. , 2019, Journal of Alzheimer's disease : JAD.
[7] Philip S. Insel,et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease , 2019, EMBO molecular medicine.
[8] P. Calabresi,et al. Neurofilament light chain as a biomarker in neurological disorders , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.
[9] Stephen F. Carter,et al. Astrocyte Biomarkers in Alzheimer's Disease. , 2019, Trends in molecular medicine.
[10] J. Kramer,et al. A comparison of biofluid cytokine markers across platform technologies: Correspondence or divergence? , 2018, Cytokine.
[11] J. Kassubek,et al. Serum GFAP as a biomarker for disease severity in multiple sclerosis , 2018, Scientific Reports.
[12] Prashanthi Vemuri,et al. Resistance vs resilience to Alzheimer disease , 2018, Neurology.
[13] C. Jack,et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.
[14] S. DeKosky,et al. Glymphatic system disruption as a mediator of brain trauma and chronic traumatic encephalopathy , 2018, Neuroscience & Biobehavioral Reviews.
[15] Alzheimer's Disease Neuroimaging Initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease , 2017 .
[16] Henrik Zetterberg,et al. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease , 2017, JAMA neurology.
[17] Manoj Kumar,et al. INGE GRUNDKE-IQBAL AWARD FOR ALZHEIMER’S RESEARCH: NEUROTOXIC REACTIVE ASTROCYTES ARE INDUCED BY ACTIVATED MICROGLIA , 2019, Alzheimer's & Dementia.
[18] Henrik Zetterberg,et al. Neurofilament Light: A Dynamic Cross-Disease Fluid Biomarker for Neurodegeneration , 2016, Neuron.
[19] K. Blennow,et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis , 2016, The Lancet Neurology.
[20] Stephen F. Carter,et al. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer’s disease , 2016, Brain : a journal of neurology.
[21] Kevin K. W. Wang,et al. Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker , 2015, Trends in Neurosciences.
[22] Maiken Nedergaard,et al. The Glymphatic System: A Beginner’s Guide , 2015, Neurochemical Research.
[23] O. Garaschuk,et al. Neuroinflammation in Alzheimer's disease , 2015, The Lancet Neurology.
[24] M. Heneka,et al. Innate immunity in Alzheimer's disease , 2015, Nature Immunology.
[25] Maiken Nedergaard,et al. Biomarkers of Traumatic Injury Are Transported from Brain to Blood via the Glymphatic System , 2015, The Journal of Neuroscience.
[26] Robert A. Koeppe,et al. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET , 2015, Alzheimer's & Dementia.
[27] J. Middeldorp,et al. Glial fibrillary acidic protein isoform expression in plaque related astrogliosis in Alzheimer's disease , 2014, Neurobiology of Aging.
[28] K. Sharkey,et al. Novel functional roles for enteric glia in the gastrointestinal tract , 2012, Nature Reviews Gastroenterology &Hepatology.
[29] G. E. Vates,et al. A Paravascular Pathway Facilitates CSF Flow Through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid β , 2012, Science Translational Medicine.
[30] B. Barres,et al. Genomic Analysis of Reactive Astrogliosis , 2012, The Journal of Neuroscience.
[31] Ove Almkvist,et al. Evidence for Astrocytosis in Prodromal Alzheimer Disease Provided by 11C-Deuterium-L-Deprenyl: A Multitracer PET Paradigm Combining 11C-Pittsburgh Compound B and 18F-FDG , 2012, The Journal of Nuclear Medicine.
[32] Nick C Fox,et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[33] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[34] N. Bogdanovic,et al. Blood-brain barrier alterations in ageing and dementia , 2009, Journal of the Neurological Sciences.
[35] Sid E O'Bryant,et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study. , 2008, Archives of neurology.
[36] N. Belyaev,et al. Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. , 2008, Current Alzheimer research.
[37] Milos Pekny,et al. Redefining the concept of reactive astrocytes as cells that remain within their unique domains upon reaction to injury , 2006, Proceedings of the National Academy of Sciences.
[38] G. Leuba,et al. Neuronal and Nonneuronal Quantitative BACE Immunocytochemical Expression in the Entorhinohippocampal and Frontal Regions in Alzheimer’s Disease , 2005, Dementia and Geriatric Cognitive Disorders.
[39] T. Wyss-Coray,et al. Adult mouse astrocytes degrade amyloid-β in vitro and in situ , 2003, Nature Network Boston.
[40] J. Schneider,et al. Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease , 2002, Annals of neurology.
[41] J. Wegiel,et al. Microglial cells are the driving force in fibrillar plaque formation, whereas astrocytes are a leading factor in plaque degradation , 2000, Acta Neuropathologica.
[42] H. Braak,et al. Amyloid β-protein (Aβ)-containing astrocytes are located preferentially near N-terminal-truncated Aβ deposits in the human entorhinal cortex , 2000, Acta Neuropathologica.
[43] M. Albert,et al. Age at onset of Alzheimer's disease , 1994, Neurology.
[44] J. Haines,et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.
[45] Virginia M. Y. Lee,et al. Neuronal modulation of schwann cell glial fibrillary acidic protein (GFAP) , 1989, Journal of neuroscience research.